IL318241A - Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer - Google Patents
Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancerInfo
- Publication number
- IL318241A IL318241A IL318241A IL31824125A IL318241A IL 318241 A IL318241 A IL 318241A IL 318241 A IL318241 A IL 318241A IL 31824125 A IL31824125 A IL 31824125A IL 318241 A IL318241 A IL 318241A
- Authority
- IL
- Israel
- Prior art keywords
- inhibitors
- hgf
- cancer
- treatment
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263367949P | 2022-07-08 | 2022-07-08 | |
| US202263370501P | 2022-08-05 | 2022-08-05 | |
| PCT/EP2023/068862 WO2024008929A1 (en) | 2022-07-08 | 2023-07-07 | Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL318241A true IL318241A (en) | 2025-03-01 |
Family
ID=87418784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL318241A IL318241A (en) | 2022-07-08 | 2023-07-07 | Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20260137681A1 (en) |
| EP (1) | EP4551226A1 (en) |
| JP (1) | JP2025522965A (en) |
| KR (1) | KR20250044679A (en) |
| CN (1) | CN119654152A (en) |
| AU (1) | AU2023303878A1 (en) |
| CA (1) | CA3261476A1 (en) |
| IL (1) | IL318241A (en) |
| MX (1) | MX2025000325A (en) |
| TW (1) | TW202421146A (en) |
| WO (1) | WO2024008929A1 (en) |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2210607B1 (en) | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| GEP20125658B (en) | 2006-11-22 | 2012-10-10 | Incyte Corp | Imidazotriazines and imidazo pyrimidines as kinase inhibitors |
| DE102007032507A1 (en) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | pyridazinone derivatives |
| PT3511330T (en) | 2009-12-31 | 2020-12-24 | Hutchison Medipharma Ltd | Synthetic intermediate useful in the preparation of triazolopyridine c-met inhibitors |
| DK3686193T3 (en) | 2011-07-27 | 2022-05-30 | Astrazeneca Ab | 2- (2,4,5-SUBSTITUTED ANILINO) PYRIMIDINE COMPOUNDS |
| US9034885B2 (en) | 2012-01-13 | 2015-05-19 | Acea Biosciences Inc. | EGFR modulators and uses thereof |
| LT2964638T (en) | 2013-03-06 | 2017-12-27 | Astrazeneca Ab | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor |
| CN104230922B (en) | 2013-06-19 | 2016-12-28 | 中国科学院上海药物研究所 | One class five-ring heterocycles pyridine compounds and their and its production and use |
| ES3069593T3 (en) | 2013-08-23 | 2026-06-09 | Neupharma Inc | Quinazolin-8-yl derivatives for use in methods of treating melanoma, non-small cell lung cancer, thyroid cancer, ovarian cancer, or colon cancer |
| GB201400034D0 (en) | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
| US20170166598A1 (en) | 2014-05-13 | 2017-06-15 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| CN105315259B (en) | 2014-07-29 | 2018-03-09 | 上海艾力斯医药科技有限公司 | Pyridine amine pyrimidine derivates, its preparation method and application |
| EP3205650B1 (en) | 2014-10-11 | 2021-08-04 | Shanghai Hansoh Biomedical Co., Ltd. | Egfr inhibitor, and preparation and application thereof |
| EP3929190B1 (en) | 2014-10-13 | 2024-12-25 | Yuhan Corporation | Compounds and compositions for modulating egfr mutant kinase activities |
| CN111170998B (en) | 2014-11-05 | 2023-04-11 | 益方生物科技(上海)股份有限公司 | Pyrimidine or pyridine compound, preparation method and medical application thereof |
| AU2015360360B2 (en) | 2014-12-11 | 2020-06-25 | Beta Pharma (Shanghai) Co., Ltd. | Substituted 2-anilinopyrimidine derivatives as EGFR modulators |
| CN107614503B (en) | 2015-04-29 | 2020-03-10 | 广东众生药业股份有限公司 | Fused or tricyclic arylpyrimidine compounds as kinase inhibitors |
-
2023
- 2023-07-07 CA CA3261476A patent/CA3261476A1/en active Pending
- 2023-07-07 IL IL318241A patent/IL318241A/en unknown
- 2023-07-07 AU AU2023303878A patent/AU2023303878A1/en active Pending
- 2023-07-07 WO PCT/EP2023/068862 patent/WO2024008929A1/en not_active Ceased
- 2023-07-07 US US18/992,063 patent/US20260137681A1/en active Pending
- 2023-07-07 CN CN202380057880.3A patent/CN119654152A/en active Pending
- 2023-07-07 EP EP23744062.3A patent/EP4551226A1/en active Pending
- 2023-07-07 TW TW112125453A patent/TW202421146A/en unknown
- 2023-07-07 JP JP2025500852A patent/JP2025522965A/en active Pending
- 2023-07-07 KR KR1020257003850A patent/KR20250044679A/en active Pending
-
2025
- 2025-01-08 MX MX2025000325A patent/MX2025000325A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3261476A1 (en) | 2024-01-11 |
| CN119654152A (en) | 2025-03-18 |
| JP2025522965A (en) | 2025-07-17 |
| US20260137681A1 (en) | 2026-05-21 |
| WO2024008929A1 (en) | 2024-01-11 |
| MX2025000325A (en) | 2025-04-02 |
| AU2023303878A1 (en) | 2025-02-27 |
| EP4551226A1 (en) | 2025-05-14 |
| TW202421146A (en) | 2024-06-01 |
| KR20250044679A (en) | 2025-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220807A1 (en) | NEW EGFR INHIBITORS | |
| IL317733A (en) | Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer | |
| MX2022014903A (en) | EGFR TKI FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER. | |
| MX2009002585A (en) | Quinazoline based egfr inhibitors containing a zinc binding moiety. | |
| UA100540C2 (en) | 2-benzylpyridazinone derivatives as met kinase inhibitors | |
| IL173081A0 (en) | Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer | |
| WO2008033748A3 (en) | Quinazoline based egfr inhibitors containing a zinc binding moiety | |
| JOP20220182A1 (en) | Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer | |
| IL315848A (en) | Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer | |
| IL195152A0 (en) | Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders | |
| EA201100334A1 (en) | BICYCLIC DERIVATIVES OF TRIAZOLE FOR THE TREATMENT OF TUMORS | |
| EA202192552A1 (en) | OSIMERTINIB FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER | |
| EP2205077A4 (en) | Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors | |
| MX2020012540A (en) | Use of cdk4/6 inhibitor in combination with egfr inhibitor in the preparation of medicament for treating tumor diseases. | |
| IL321393A (en) | Ctps1 inhibitors for use in the treatment of ctps2 deficient cancer | |
| IL183448A0 (en) | Combination of tyrosine kinase inhibitor and her-2/neu for cancer therapy | |
| WO2004013091A3 (en) | 4-anilido substituted quinazolines and use thereof as inhibitors of epidermal growth factor receptor kinases | |
| MX2022008874A (en) | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer. | |
| EP4097140A4 (en) | Use of quinazoline-based tyrosine kinase inhibitors for the treatment of cancers with nrg1 fusions | |
| PH12021552342A1 (en) | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma | |
| HK40126841A (en) | Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer | |
| HK40126792A (en) | Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer | |
| MX2010004259A (en) | Improved antitumoral treatments. | |
| MX2021013982A (en) | Compound for inhibiting egfr kinase and preparation method and use thereof. | |
| HK40085112A (en) | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |